Lepu Medical's (300003.SZ) subsidiary receives U.S. FDA approval for clinical trial of MWN117 injection

Zhitong Finance APP news, Lepu Medical (300003.SZ) announced that the company was informed today that its controlling subsidiary Shanghai Minwei Biotechnology Co., Ltd. (hereinafter referred to as "Shanghai Minwei Biotechnology") has received a notice from the U.S. Food and Drug Administration (hereinafter referred to as "U.S. FDA") agreeing to the conduct of clinical trials for MWN117 injection (Study May Proceed Letter, IND number: 182860).